Back to Search
Start Over
Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina
- Source :
- American Journal of Ophthalmology Case Reports, Vol 26, Iss , Pp 101519- (2022)
- Publication Year :
- 2022
- Publisher :
- Elsevier, 2022.
-
Abstract
- Purpose: Cutaneous melanoma metastatic to the vitreous/retina is rare but increasingly common. Due to the potential of recurrent disease with current treatment options and the propensity for these eyes to develop neovascularization, these eyes can pose a treatment challenge and novel management strategies are needed. This case series explores the use of combination, sequential intravitreous melphalan and bevacizumab. Observation: Two eyes of two patients with cutaneous melanoma metastatic to the vitreoretina were eye treated with combination intravitreous melphalan (10-30 mcg) and bevacizumab (1.25 mg) given sequentially during the same office visit, at monthly intervals. Both cases had control of disease at 7- and 12-months follow up. Furthermore, treatment reversed neovascular glaucoma and dramatically improved vision in the eye of one patient; and stabilized vision without the development of neovascularization in the eye of the other patient. There were no ocular adverse events noted in either eye. Conclusions and Importance: Combination, sequential intravitreous melphalan and bevacizumab is well-tolerated and an attractive approach for treating eyes with intraocular metastatic melanoma.
Details
- Language :
- English
- ISSN :
- 24519936
- Volume :
- 26
- Issue :
- 101519-
- Database :
- Directory of Open Access Journals
- Journal :
- American Journal of Ophthalmology Case Reports
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1e00908bf904a4ab57ae7a9133f4eba
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.ajoc.2022.101519